![]() |
市场调查报告书
商品编码
1830952
主动脉支架移植物市场Aortic Stent Grafts Market |
主动脉支架移植物市场预计将从 2024 年的 26.2 亿美元扩大到 2031 年的 40.3 亿美元,预计 2025 年至 2031 年的复合年增长率为 6.5%。
市场洞察与分析师观点:支架移植物是一种专门用于治疗主动脉瘤的医疗器械,采用微创血管内技术。该装置由一层薄金属网(称为支架)组成,金属网外包裹着一层薄聚酯纤维(称为移植物)。支架经由导管插入主动脉并定位。一旦定位,支架移植物就会保持固定,允许血液流过,从而保护受影响的主动脉部分并防止动脉瘤破裂。主动脉瘤发生率的上升以及对血管内修復等微创手术的日益青睐是推动主动脉支架移植物市场成长的关键因素。然而,市场参与者的产品召回对市场扩张构成了挑战。此外,预计技术进步和製造商的策略性倡议将在不久的将来为主动脉支架移植物市场带来新的趋势。
成长驱动因素:医学科技的进步推动了微创设备的发展,这些设备以创伤较小或非侵入性的替代方法取代了传统的、痛苦的手术方法。微创技术在外科领域越来越受欢迎,包括心臟外科。血管内动脉瘤修復术 (EVAR) 是一种治疗腹主动脉瘤的微创方法,透过比开胸心臟手术更小的切口将支架移植物插入主动脉受影响的区域,从而促进更快癒合并缩短手术时间。 JAMA Network 于 2022 年 5 月发表的一项研究比较了 EVAR 与 AAA 的开放性修復的长期结果,显示血管内修復比开放修復腹主动脉瘤的风险更低。此外,外科医生因其优势而采用微创技术,医疗设备和外科手术技术的进步也促进了其更广泛的接受。因此,医疗机构正在投资培训医护人员併购置必要的设备,以满足对选择性主动脉瘤修復手术日益增长的需求,从而增强患者的治疗选择和整体医疗保健体验。
因此,对微创设备日益增长的需求是主动脉支架移植市场成长的重要驱动力。
战略洞察
报告细分和范围:「2031 年全球主动脉支架移植物市场分析」透过研究以下细分进行:产品类型和最终用户。
細項分析:依产品类型,市场分为腹主动脉支架移植物和胸主动脉支架移植物。 2023年,腹主动脉支架移植物占据主动脉支架移植物市场的最大份额。
就最终用户而言,市场分为医院和门诊手术中心。由于专业且复杂的科学仪器的普及,预计医院领域将在2023年至2031年期间占据相当大的市场份额。
区域分析:全球主动脉支架移植市场报告涵盖北美、欧洲、亚太、南美和中美以及中东和非洲。
就收入而言,2023 年北美占据主动脉支架移植物市场的首位。由于吸烟者数量众多且人们强烈倾向于微创手术,主动脉瘤的盛行率不断上升,加上美国优惠的报销政策和不断上涨的医疗支出,这些都是推动该地区市场成长的关键因素。例如,美国疾病管制与预防中心 (CDC) 于 2021 年 9 月发布的资料显示,吸烟史约占腹主动脉瘤的 75%,美国预防服务工作小组建议有吸烟史的 65 岁及以上男性接受腹主动脉瘤超音波筛检,即使没有症状。此外,血管外科学会 (SVS) 报告称,美国每年约有 20 万人被诊断出患有 AAA。因此,人群中主动脉瘤等心血管疾病发生率的不断增加推动了美国对主动脉支架移植的需求,促进了主动脉支架移植市场的成长。
主动脉支架移植物市场报告范围
产业发展与未来机会:主动脉支架移植物市场的预测可以帮助利害关係人规划其成长策略。根据主要市场参与者的新闻稿,以下是一些重点倡议:
2023年9月,微创心脉科技旗下三款主动脉介入产品获得泰国食品药物管理局(TFDA)批准,包括Castor分支型主动脉覆膜支架及输送系统、Minos腹主动脉覆膜支架及输送系统以及Hercules低剖面胸主动脉覆膜支架系统,用于治疗胸主动脉和腹主动脉疾病,目前已在泰国註册。
2023年3月,Bolton Medical, Inc. 的 RelayPro 胸主动脉支架移植物系统获得美国食品药品监督管理局 (FDA) 批准,该系统包含一根输送导管和由镍钛合金、聚酯和铂铱合金製成的管状植入物,用于修復主动脉损伤,尤其是降主动脉损伤。 2023年3月,Vector Biolabs 宣布完成设施扩建,其中包括办公空间、仓库、品管实验室和无尘室生产套件。该公司表示,新增产能将使其能够随着需求成长保持快速反应,并扩展其服务范围,包括新产品表征和品质控制服务。
2021年5月,Endologix LLC在获得加拿大卫生部批准后,在加拿大推出了ALTO腹部支架移植物,该产品也已在阿根廷获得商业批准。此次上市旨在提升公司在全球市场的影响力。竞争格局与主要公司:主动脉支架移植物市场的主要参与者包括ENDOLOGIX INC、Terumo Corporation、Radcliffe Medical Media、Cook、MicroPort Scientific Corporation、Corcym、LeMaitre Vascular, Inc、WL Gore & Associates, Inc.、JOTEC GmbH和美敦力。这些公司专注于开发新技术、改进现有产品并拓展地理范围,以满足日益增长的全球消费者需求并拓宽其特色产品组合。
The aortic stent grafts market is anticipated to expand from US$ 2.62 billion in 2024 to US$ 4.03 billion by 2031, with a projected CAGR of 6.5% from 2025 to 2031.
Market Insights and Analyst Perspective:A stent graft is a specialized medical device intended for the treatment of aortic aneurysms using minimally invasive endovascular techniques. This device consists of a thin metal mesh known as the stent, which is covered by a thin polyester fabric referred to as the graft. It is introduced via a catheter and positioned within the aorta. Once positioned, the stent graft remains fixed, allowing blood to flow through it, thereby safeguarding the affected section of the aorta and preventing aneurysm rupture. The rising incidence of aortic aneurysms and the growing preference for minimally invasive procedures like endovascular repairs are key factors propelling the growth of the aortic stent grafts market. However, product recalls by market players pose challenges to market expansion. Additionally, advancements in technology and strategic initiatives by manufacturers are expected to introduce new trends in the aortic stent grafts market in the near future.
Factors Driving Growth:Advancements in medical science and technology have led to the development of minimally invasive devices, which replace traditional, painful surgical methods with less invasive or noninvasive alternatives. Minimally invasive techniques have become increasingly popular in surgical disciplines, including cardiac surgery. Endovascular aneurysm repair (EVAR) is a minimally invasive approach for treating abdominal aortic aneurysms, performed by inserting a stent graft into the affected area of the aorta through a smaller incision than that required for open cardiac surgery, thus promoting quicker healing and reducing procedure duration. A study published by JAMA Network in May 2022 compared the long-term outcomes of EVAR with open repair of AAA, indicating that endovascular repair carries a lower risk than open repair for abdominal aortic aneurysms. Furthermore, surgeons are adopting minimally invasive techniques due to their advantages, and improvements in medical devices and surgical expertise have facilitated broader acceptance. Consequently, healthcare institutions are investing in training their medical personnel and acquiring the necessary equipment to address the rising demand for elective aortic aneurysm repair surgeries, thereby enhancing treatment options and overall healthcare experiences for patients.
Thus, the growing demand for minimally invasive devices is a significant driver of the aortic stent grafts market growth.
Strategic Insights
Report Segmentation and Scope:The "global aortic stent grafts market analysis to 2031" has been conducted by examining the following segments: product type and end user.
Segmental Analysis:By product type, the market is divided into abdominal aortic and thoracic aortic stent grafts. The abdominal aortic stent graft segment accounted for the largest share of the aortic stent grafts market in 2023.
Regarding end users, the market is categorized into hospitals and ambulatory surgical centers. The hospital segment is expected to capture a significant market share from 2023 to 2031, due to the availability of specialized and complex scientific instruments.
Regional Analysis:The global aortic stent grafts market report encompasses North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
In terms of revenue, North America led the aortic stent grafts market in 2023. The increasing prevalence of aortic aneurysms, attributed to a high number of smokers and a strong preference for minimally invasive procedures, along with favorable reimbursement policies and rising healthcare expenditures in the US, are key factors driving market growth in the region. For example, data from the Centers for Disease Control and Prevention (CDC) published in September 2021 indicates that a history of smoking accounts for approximately 75% of abdominal aortic aneurysms, and men aged 65 and older with a smoking history are advised to undergo abdominal aortic aneurysm ultrasound screening, even if asymptomatic, by the U.S. Preventive Services Task Force. Additionally, the Society for Vascular Surgery (SVS) reports that around 200,000 individuals are diagnosed with AAA in the US annually. Therefore, the increasing incidence of cardiovascular issues such as aortic aneurysms among the population is driving the demand for aortic stent grafts in the US, facilitating the growth of the aortic stent grafts market.
Aortic Stent Grafts Market Report Scope
Industry Developments and Future Opportunities:The forecast for the aortic stent grafts market can assist stakeholders in planning their growth strategies. According to press releases from key market players, several initiatives are highlighted below:
In September 2023, MicroPort Endovastec received approval from the Thailand Food and Drug Administration (TFDA) for three aortic intervention products, including the Castor Branched Aortic Stent-Graft and Delivery System, the Minos Abdominal Aortic Stent-Graft and Delivery System, and the Hercules Thoracic Stent Graft System with Low Profile Delivery System. These products are designed to treat thoracic and abdominal aortic diseases and are now registered for use in Thailand.
In March 2023, Bolton Medical, Inc. obtained U.S. Food & Drug Administration (FDA) approval for its RelayPro Thoracic Stent-Graft System, which includes a delivery catheter and tube-shaped implants made of nitinol, polyester, and platinum-iridium, used for repairing damage in the aorta, particularly in the descending thoracic aorta.In March 2023, Vector Biolabs announced the completion of a facility expansion, which includes office space, warehouses, QC labs, and a cleanroom manufacturing suite. The company stated that this additional capacity will enable it to maintain fast response times as demand grows and expand its offerings to include new product characterization and quality control services.
In May 2021, Endologix LLC launched the ALTO Abdominal Stent Graft in Canada after receiving approval from Health Canada, and it has also been commercially approved in Argentina. This launch aims to enhance the company's global presence in the market.Competitive Landscape and Key Companies:Key players in the aortic stent grafts market include ENDOLOGIX INC, Terumo Corporation, Radcliffe Medical Media, Cook, MicroPort Scientific Corporation, Corcym, LeMaitre Vascular, Inc, W. L. Gore & Associates, Inc., JOTEC GmbH, and Medtronic. These companies are focused on developing new technologies, enhancing existing products, and expanding geographically to meet the growing global consumer demand and broaden their specialty product portfolios.